Investors are overly focused on one issue with this stock while the company is making progress on many fronts.
News & Analysis: Akcea Therapeutics, Inc.
AKCA earnings call for the period ending September 30, 2019.
Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
A licensing deal gives investors confidence in a turnaround.
Find out which of these companies investors are the most nervous about.
AKCA earnings call for the period ending June 30, 2019.
AKCA earnings call for the period ending March 31, 2019.
AKCA earnings call for the period ending December 31, 2018.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
A surprise rejection is a major setback for both partners, but not the end of the line.